Trial Profile
A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 11 Jun 2019 Results published in the Novartis media release
- 11 Jun 2019 According to a Novartis media release, results from the two phase II studies (NCT03063086 and NCT03108027) showed a significant improvement over the standard treatment.
- 22 May 2019 Results presented in a Sosei Heptares media release.